Anju Ghangurde on Muck Rack

Anju Ghangurde

Verified
Mahārāshtra
As seen in: Scrip, The Pink Sheet, Informa, Citeline, Generics Bulletin, HBW Insight, In Vivo, Medtech Insight
Executive Editor (Asia Pacific), Scrip/Pink Sheet, @Citeline @NorstellaCo but views own; believe in karma & that moms can move mountains
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Anju

Contact Anju, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Indian Think Tank’s Pre-Grant Opposition Time Bar: Tighter Window Or Closed Door?

|
By Anju Ghangurde Verified
| The Pink Sheet Verified
The apex public policy think tank of the Government of India calls for a time-bound patent opposition and grant process. Can it contain misuse of the norms in pharma or is it “cumulative and disproportionate", as some legal experts say. Tighter window or closed door?
Open in Who Shared Issue with article?

API Snag To Hit Dr Reddy’s Semaglutide Supplies, CEO Expects Fix Later This Year

|
By Anju Ghangurde Verified
| Scrip Verified
Dr Reddy's semaglutide supply is hit by impurity issues, with Canadian market deliveries also expected to be affected down the line. Partner Torrent is separately making a voluntary recall of certain batches of semaglutide injection following a product recall notification from Dr Reddy’s.
Open in Who Shared Issue with article?

Treat Now, Pay Later: How Immuneel Hopes To Unlock CAR-T Access In India

|
By Anju Ghangurde Verified
| Scrip Verified
Immuneel offers zero cost EMI program for its CAR-T cell therapy in India. Can the model meaningfully scale access or improve treatment initiation rates, as seen in similar prior big pharma initiatives? Can EMI financing make CAR-T therapy accessible in India?
Open in Who Shared Issue with article?
See all 1,689 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified